Monitor upcoming regulatory filings or clinical trial announcements for progress updates on the CAPTN-3 platform. The SAB formation signals strategic focus but does not alter near-term valuation without additional data.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 23 $4.55entry
- T+1 · 7mo ago −0.22%α −1.00% · $4.54
- T+5 · 7mo ago −7.03%α −8.51% · $4.23
- T+20 · 6mo ago −34.51%α −39.14% · $2.98
- T+60 · 4mo ago −68.13%α −73.15% · $1.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Purple Biotech announced the formation of a Scientific Advisory Board (SAB) composed of leading experts in immunotherapy and oncology to guide the development of its CAPTN-3 tri-specific antibody platform. The SAB includes specialists in T-cell and NK cell biology with direct experience in developing approved T-cell engager therapies.
Key Facts
- Purple Biotech established a Scientific Advisory Board (SAB) to support development of its CAPTN-3 tri-specific antibody platform.
- SAB members include Dr. Amir Horowitz (NK cell biology), Dr. Afshin Dowlati (early-phase clinical development in solid tumors), Dr. Alexander Shoushtari (melanoma and T-cell engager development), and Dr. Max S. Topp (early clinical development of blinatumomab).
- The CAPTN-3 platform is in preclinical development and focuses on masked tri-specific antibodies targeting 5T4 (IM1240) and TROP2 (IM1305).
- No financial terms, clinical data, or material agreements were disclosed in the filing.
Financial Impact
No immediate financial impact; advisory board formation is a strategic development without direct monetary implications.
Risk Factors
- CAPTN-3 remains in preclinical development with no guarantee of successful clinical translation.
- Company has limited financial resources (market cap $5M) and may require future capital raises, potentially dilutive to shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-046868 |
| Document: ea0286950-6k_purple.htm | 0001213900-26-046868 |
| Document: 0001213900-26-046868-index-headers.html | 0001213900-26-046868 |
| Document: 0001213900-26-046868-index.html | 0001213900-26-046868 |
| Document: 0001213900-26-046868.txt | 0001213900-26-046868 |
Track record
14 reports on PPBT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
- Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
- Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
- Aug 10, 202614w ago 6-K Neutral 4/10 Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
- Aug 7, 202614w ago 6-K Neutral 4/10 Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
- May 15, 202626w ago Press Release Neutral 4/10 Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers